A study to investigate the response to osimertinib in pretreated patients with Leptomeningeal Metastases regardless of T790M status
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer